OBJECTIVE: To report the occurrence of @entity7995 after @entity6192 vaccination in two @entity1 . DESIGN: Observational case reports, review of literature. METHODS: Description of clinical history, examination, neuroimaging, and further studies in two @entity1 experiencing @entity7995 in temporal association with @entity6192 vaccination. MAIN OUTCOME MEASURES: Visual acuity, visual fields. RESULTS: Two @entity1 , 39 and 23 years of age, were seen with acute @entity7995 1 month and 2 weeks, respectively, after @entity6192 booster vaccination and successfully treated with intravenous @entity1667 . The first @entity1 had a typical presentation and course of unilateral retrobulbar @entity7995 with excellent visual recovery. The second @entity1 had a bilateral anterior @entity7995 and has required chronic immunosuppression to maintain his vision. @entity5995 and optic nerve autoantibodies were present in the second @entity1 . No cross-reactive epitopes between @entity6192 vaccine and retina/optic nerve were identified. CONCLUSION: @entity7995 is a potential adverse reaction of @entity6192 vaccination.

XXXX after @entity6192 vaccination.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity6192 :: ('1392', 'Species') :: ['anthrax'] @entity1667 :: ('MESH:D008775', 'Chemical') :: ['methylprednisolone'] @entity7995 :: ('MESH:D009902', 'Disease') :: ['optic neuritis', 'Optic neuritis'] @entity5995 :: ('MESH:D012172', 'Chemical') :: ['Retinal']
@entity7995 :: (MESH:D009902,Disease) :: ['Optic neuritis']
